We’re excited to share the latest update to CKB CORE, Genomenon’s free-tier access to the Cancer Knowledgebase (CKB) – your trusted source for expertly curated oncology variant data.
This quarter, CKB CORE continues to offer free access to 50 clinically significant cancer genes, selected for their diagnostic relevance and therapeutic actionability across solid tumors and hematologic malignancies. Each includes expert-reviewed variant data, literature-backed evidence, drug associations, and clinical trial links.
New this quarter: 14 tyrosine kinase genes – key drivers of oncogenic signaling and drug resistance – have been added to the rotating gene set:.
ABL1, AXL, BTK, CSF1R, ERBB3, ERBB4, JAK1, KDR, MERTK, MST1R, NTRK1, NTRK2, PDGFRB, SRC, TYRO3
These join core kinase genes always included in the full CKB database, such as FLT3, KIT, FGFR1-3, ALK, ROS1, RET, JAK2, and JAK3.
Explore the CKB CORE update in our latest blog: |
